Accueil>>Signaling Pathways>> Neuroscience>> Beta-secretase>>AZD3839

AZD3839

Catalog No.GC14130

AZD3839 est un inhibiteur puissant et sélectif de BACE1 actif par voie orale et perméable au cerveau (Ki = 26 nM). AZD3839 montre une sélectivité de 14 et> 1000 fois contre BACE2 et la cathepsine D, respectivement. AZD3839 présente une diminution dose-dépendante du temps du plasma, du cerveau et du liquide céphalo-rachidien Aβ ; chez la souris, le cobaye et le primate non humain. AZD3839 peut être utilisé pour la recherche sur la maladie d'Alzheimer.

Products are for research use only. Not for human use. We do not sell to patients.

AZD3839 Chemical Structure

Cas No.: 1227163-84-9

Taille Prix Stock Qté
5mg
96,00 $US
En stock
10mg
146,00 $US
En stock
50mg
483,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Description:

IC50: 16.7 nM for BACE1

β-Site amyloid precursor protein cleaving enzyme1 (BACE1) is one of the key enzymes involved in the processes of the amyloid precursor protein (APP) and formation of amyloid β peptide (Aβ) species. Because cerebral deposition of Aβ species is possibly critical for the pathogenesis of Alzheimer disease, BACE1 has emerged as a key target for the treatment of this disease. AZD3839 is a potent and selective BACE1 inhibitor.

In vitro: AZD3839 concentration-dependently inhibited BACE1 activity in a biochemical fluorescence resonance energy transfer assay, Aβ and sAPPβ release from modified and wild-type human SH-SY5Y cells and mouse N2A cells as well as from guinea pig and mouse primary cortical neurons. Selectivity against BACE2 and cathepsin D was 14 and >1000-fold, respectively [1].

In vivo: AZD3839 exhibited dose- and time-dependent lowering of plasma, brain, and cerebrospinal fluid Aβ levels in mouse, guinea pig, and non-human primate. PK/PD analyses of mouse and guinea pig data showed a good correlation between the potency of AZD3839 in primary cortical neurons and in vivo brain effects [1].

Clinical trial: Based on the pharmacological profile and its drug like properties, AZD3839 has been progressed into Phase 1 clinical trials in man [2].

Reference:
[1] Jeppsson F, Eketj?ll S, Janson J, Karlstr?m S, Gustavsson S, Olsson LL, Rades?ter AC, Ploeger B, Cebers G, Kolmodin K, Swahn BM, von Berg S, Bueters T, F?lting J.  Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.
[2] https://clinicaltrials. gov/ct2/show/NCT01348737?term=AZD3839&rank=1

Avis

Review for AZD3839

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZD3839

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.